Beta
Back to JNJ.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-and-debt-chart

JNJ Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q1'26, Johnson & Johnson (JNJ) reported cash and short-term investments at $22.1B, marking a modest increase from $20.1B in Q4'25 but remaining below the peak of $38.8B observed in Q1'25. Meanwhile, total debt stood at $17.5B, reflecting a significant 64% decline from $47.9B in Q4'25 and the lowest level in the period, resulting in a positive net cash position of approximately $4.6B. Over the timeframe from Q2'23 to Q1'26, cash levels exhibited volatility, starting at $28.5B and dipping to $18.6B in Q3'25 before the recent uptick, with a notable surge to $38.8B in Q1'25 likely driven by operational cash flows or asset sales. Debt trended upward from $45.6B in Q2'23 to a high of $52.3B in Q1'25 amid potential expansions or acquisitions, but has since declined sharply by over 66% from that peak, suggesting aggressive deleveraging and improved balance sheet health for JNJ. This shift has narrowed the net debt gap, enhancing financial flexibility despite ongoing fluctuations in liquidity.